Moreover, current studies evaluating visfatin levels in visceral adipose tissue and liver in NAFLD and liver fibrosis are very limited, requiring future research for further evaluation. This evidence concerns the gene NAMPT and metabolic dysfunction-associated steatotic liver disease.